TNF and myeloid sarcoma: Our previous study raised the question whether the demyelinating events in patients who had previously received TNF-α blockers were the result of uncovering latent MS, onset of a novel demyelinating event (MS or MS-like syndrome), or were merely an accidental coexistence of the 2 disorders.